Balchem Co. (NASDAQ:BCPC)’s share price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $97.13 and traded as high as $99.97. Balchem shares last traded at $98.53, with a volume of 2,505 shares.
BCPC has been the subject of a number of recent analyst reports. BidaskClub downgraded Wright Medical Group from a “buy” rating to a “hold” rating in a research note on Thursday, May 23rd. Pivotal Research lifted their price objective on Tyson Foods from $40.00 to $50.00 and gave the company a “sell” rating in a research note on Monday, May 6th. HC Wainwright lifted their price objective on Cytokinetics from $21.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, May 6th. Finally, Zacks Investment Research cut Haynes International from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $112.50.
The business has a 50 day moving average of $97.13. The company has a quick ratio of 2.43, a current ratio of 3.47 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $3.20 billion, a P/E ratio of 32.73 and a beta of 1.14.
Balchem (NASDAQ:BCPC) last released its quarterly earnings data on Friday, May 3rd. The basic materials company reported $0.73 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.04. The business had revenue of $157.00 million during the quarter, compared to analysts’ expectations of $165.57 million. Balchem had a net margin of 12.20% and a return on equity of 14.11%. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.76 EPS. As a group, analysts anticipate that Balchem Co. will post 2.97 earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the company. First Hawaiian Bank lifted its position in Balchem by 68.0% in the 1st quarter. First Hawaiian Bank now owns 378 shares of the basic materials company’s stock valued at $35,000 after purchasing an additional 153 shares during the last quarter. NumerixS Investment Technologies Inc acquired a new stake in Balchem in the fourth quarter valued at approximately $39,000. Private Capital Group LLC lifted its stake in Balchem by 116.7% in the first quarter. Private Capital Group LLC now owns 572 shares of the basic materials company’s stock valued at $53,000 after acquiring an additional 308 shares during the last quarter. Parallel Advisors LLC acquired a new stake in Balchem in the first quarter valued at approximately $81,000. Finally, NN Investment Partners Holdings N.V. acquired a new stake in Balchem in the second quarter valued at approximately $164,000. 86.97% of the stock is owned by institutional investors.
About Balchem (NASDAQ:BCPC)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Read More: What does an equal weight rating mean?
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.